Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

NCT02309580 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
14
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators